BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1150 related articles for article (PubMed ID: 25914474)

  • 21. Comparison of the antiviral effects of different nucleos(t)ide analogues in chinese patients with chronic hepatitis B: a head-to-head study.
    Yu S; Zhou Q; Zhao XM; Yuan M; Wang CT; Cheng XG; Zhang ZH; Li X
    Saudi J Gastroenterol; 2014; 20(6):350-5. PubMed ID: 25434315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B.
    Lai CL; Wong D; Ip P; Kopaniszen M; Seto WK; Fung J; Huang FY; Lee B; Cullaro G; Chong CK; Wu R; Cheng C; Yuen J; Ngai V; Yuen MF
    J Hepatol; 2017 Feb; 66(2):275-281. PubMed ID: 27639844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
    Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
    World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nucleoside analogues improve the short-term and long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure.
    Chen T; He Y; Liu X; Yan Z; Wang K; Liu H; Zhang S; Zhao Y
    Clin Exp Med; 2012 Sep; 12(3):159-64. PubMed ID: 22002708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
    Chen CH; Wang JH; Lu SN; Hu TH; Hung CH; Chang MH; Changchien CS; Lee CM
    Antivir Ther; 2012; 17(4):701-9. PubMed ID: 22358132
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of HBcrAg with Intrahepatic Hepatitis B Virus Total DNA and Covalently Closed Circular DNA in HBeAg-Positive Chronic Hepatitis B Patients.
    Wang L; Cao X; Wang Z; Gao Y; Deng J; Liu X; Zhuang H
    J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
    Lai CL; Shouval D; Lok AS; Chang TT; Cheinquer H; Goodman Z; DeHertogh D; Wilber R; Zink RC; Cross A; Colonno R; Fernandes L;
    N Engl J Med; 2006 Mar; 354(10):1011-20. PubMed ID: 16525138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.
    Koffi J; Egounlety R; Pradat P; Lebosse F; Si-Ahmed SN; Lussier V; Chevallier P; Bailly F; Zoulim F
    Eur J Gastroenterol Hepatol; 2014 Feb; 26(2):146-54. PubMed ID: 24025974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Multicenter Study of the Antiviral Efficacy of Entecavir Monotherapy Compared to Lamivudine Monotherapy in Children with Nucleos(t)ide-naïve Chronic Hepatitis B.
    Lee KJ; Choe BH; Choe JY; Kim JY; Jeong IS; Kim JW; Yang HR; Chang JY; Kim KM; Moon JS; Ko JS
    J Korean Med Sci; 2018 Feb; 33(8):e63. PubMed ID: 29441755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B.
    Hagiwara S; Kudo M; Osaki Y; Matsuo H; Inuzuka T; Matsumoto A; Tanaka E; Sakurai T; Ueshima K; Inoue T; Yada N; Nishida N
    J Med Virol; 2013 Jun; 85(6):987-95. PubMed ID: 23588724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
    Ryu HJ; Lee JM; Ahn SH; Kim DY; Lee MH; Han KH; Chon CY; Park JY
    J Med Virol; 2010 Nov; 82(11):1835-42. PubMed ID: 20872709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy.
    Chaung KT; O'Brien C; Ha NB; Nguyen NH; Trinh HN; Nguyen MH
    J Clin Gastroenterol; 2016 Apr; 50(4):338-44. PubMed ID: 26646801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
    Zheng MH; Shi KQ; Dai ZJ; Ye C; Chen YP
    Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication.
    Lutgehetmann M; Volzt T; Quaas A; Zankel M; Fischer C; Dandri M; Petersen J
    Antivir Ther; 2008; 13(1):57-66. PubMed ID: 18389899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of lamivudine plus adefovir therapy versus entecavir with or without adefovir therapy for adefovir-resistant chronic hepatitis B.
    Kang SH; Yim HJ; Kim HR; Kang K; Suh SJ; Lee HJ; Yoon EL; Kim JH; Seo YS; Yeon JE; Byun KS
    J Clin Gastroenterol; 2014; 48(10):889-95. PubMed ID: 24440937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection.
    Yuen MF; Wong DK; Sum SS; Yuan HJ; Yuen JC; Chan AO; Wong BC; Lai CL
    Am J Gastroenterol; 2005 May; 100(5):1099-103. PubMed ID: 15842584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels.
    Shi H; Han Z; Liu J; Xue J; Zhang S; Zhu Z; Xia J; Huang M
    Med Sci Monit; 2017 Nov; 23():5230-5236. PubMed ID: 29095799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients.
    Testoni B; Lebossé F; Scholtes C; Berby F; Miaglia C; Subic M; Loglio A; Facchetti F; Lampertico P; Levrero M; Zoulim F
    J Hepatol; 2019 Apr; 70(4):615-625. PubMed ID: 30529504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir.
    Son CY; Ryu HJ; Lee JM; Ahn SH; Kim DY; Lee MH; Han KH; Chon CY; Park JY
    Liver Int; 2012 Aug; 32(7):1179-85. PubMed ID: 22452737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.